Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
State-of-the-Art Immunology and Immunotherapy in Poland
share announcement

State-of-the-Art Immunology and Immunotherapy in Poland

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 2321

Special Issue Editor

Prof. Dr. Jan Zaucha

E-Mail Website
Guest Editor
Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland
Interests: lymphoma; immunotherapy; bone marrow transplantation

Special Issue Information

Dear Colleagues,

The special issue will be devoted to the state-of-the-Art of Immunotherapy in Poland especially CAR-T cell therapy both with regard to the pre-clinical and clinical aspects.

We cordially invite authors to contribute original research articles or reviews focusing on, but not limited to, the following:

  • The current status and challenges of the CAR-T cell therapy in children and adults.
  • The current knowledge regarding the attempts to improve the efficacy of CAR-T cells.
  • The barriers related to the development of CAR-T cells in solid tumors especially melanoma.
  • The insight how proteomics of CAR-T cells can help to better understand the limitations of this type of immunotherapy

Prof. Dr. Jan Zaucha
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • CAR-T cells
  • Poland
  • efficacy of CAR-T
  • solid tumors
  • melanoma
  • proteomics

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 395 KiB  
Article
Blinatumomab Prior to CAR-T Cell Therapy—A Treatment Option Worth Consideration for High Disease Burden
by Paweł Marschollek, Karolina Liszka, Monika Mielcarek-Siedziuk, Blanka Rybka, Renata Ryczan-Krawczyk, Anna Panasiuk, Igor Olejnik, Jowita Frączkiewicz, Iwona Dachowska-Kałwak, Agnieszka Mizia-Malarz, Tomasz Szczepański, Wojciech Młynarski, Jan Styczyński, Katarzyna Drabko, Grażyna Karolczyk, Ewa Gorczyńska, Jan Maciej Zaucha and Krzysztof Kałwak
Biomedicines 2022, 10(11), 2915; https://doi.org/10.3390/biomedicines10112915 - 13 Nov 2022
Cited by 1 | Viewed by 1838
Abstract
The optimal bridging therapy before CAR-T cell infusion in pediatric relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL) still remains an open question. The administration of blinatumomab prior to CAR-T therapy is controversial since a potential loss of CD19+ target cells [...] Read more.
The optimal bridging therapy before CAR-T cell infusion in pediatric relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL) still remains an open question. The administration of blinatumomab prior to CAR-T therapy is controversial since a potential loss of CD19+ target cells may negatively impact the activation, persistence, and, as a consequence, the efficacy of subsequently used CAR-T cells. Here, we report a single-center experience in seven children with chemorefractory BCP-ALL treated with blinatumomab before CAR-T cell therapy either to reduce disease burden before apheresis (six patients) or as a bridging therapy (two patients). All patients responded to blinatumomab except one. At the time of CAR-T cell infusion, all patients were in cytological complete remission (CR). Four patients had low positive PCR-MRD, and the remaining three were MRD-negative. All patients remained in CR at day +28 after CAR-T infusion, and six out of seven patients were MRD-negative. With a median follow-up of 497 days, four patients remain in CR and MRD-negative. Three children relapsed with CD19 negative disease: two of them died, and one, who previously did not respond to blinatumomab, was successfully rescued by stem cell transplant. To conclude, blinatumomab can effectively lower disease burden with fewer side effects than standard chemotherapeutics. Therefore, it may be a valid option for patients with high-disease burden prior to CAR-T cell therapy without clear evidence of compromising efficacy; however, further investigations are necessary. Full article
(This article belongs to the Special Issue State-of-the-Art Immunology and Immunotherapy in Poland)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop